WCM
ABBV icon

Westend Capital Management’s AbbVie ABBV Stock Holding History

Westend Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,500
Closed -$238K – 61
2015
Q2 		$238K Buy
+3,500
New +$228K 0.28% 58
2015
Q1 		– Sell
-20
Closed -$11K – 78
2014
Q4 		$11K Buy
+20
New +$1.26K 0.01% 92

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westend Capital Management's ABBV Position: Q1 2026 in Review

Westend Capital Management held its AbbVie (ABBV) position steady in Q1 2026 at 127 shares worth $27.6K. The position accounts for 0.01% of the portfolio, ranked #112.

Westend Capital Management first reported a position in ABBV in Q2 2013 and has held it in 17 quarters since. The position peaked at $2.33M in Q1 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Westend Capital Management held 127 shares of AbbVie worth $27.6K as of Q1 2026.
  • Westend Capital Management left its AbbVie share count unchanged in Q1 2026.
  • AbbVie made up 0.01% of Westend Capital Management's portfolio in Q1 2026, its #112 holding.
  • Westend Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 17 quarters since.
  • Westend Capital Management's AbbVie position peaked at $2.33M in Q1 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Westend Capital Management's 13F filing for Q1 2026, filed 14 Apr 2026.